All
Propranolol and PDL clear infantile hemangiomas
April 24th 2012The use of propranolol and pulsed dye laser (PDL) led to more rapid clearing of infantile hemangiomas than propranolol alone, according to a retrospective chart review presented at the 2012 annual meeting of the American Society for Laser Medicine and Surgery.
New Nd:YAG laser delivery option manages onychomycosis, study shows
April 24th 2012The cosmetic and medical aspects of onychomycosis appear to be treated effectively with 1,064 nm Nd:YAG laser therapy, said Jill Waibel, M.D., at the 2012 annual meeting of the American Society for Laser Medicine and Surgery.
3-D imaging confirms volumizing effects of fractional bipolar RF
April 24th 2012An aesthetic device that delivers bipolar radiofrequency (RF) energy via microneedling appears to achieve skin tightening, lifting and volumization that can be measured objectively through the comparison of pre- and post-procedure 3-D images, said Lori Brightman, M.D., at the 2012 annual meeting of the American Society for Laser Medicine and Surgery.
Picosecond laser shows significant promise for new era in tattoo removal
April 24th 2012Treatment with a picosecond 755 nm alexandrite laser (Cynosure) appears to be a significant advance for clearing tattoos as well as benign pigmented lesions, according to research reported at LASER 2012, the annual conference of the American Society for Laser Medicine and Surgery.
Same-day, repetitive Q-switch laser treatments boost tattoo clearance, but with diminishing returns
April 24th 2012Repetitive same-day treatment with a nanosecond pulse, Q-switched laser increases tattoo ink clearance and is safe, but the magnitude of improvement does not appear to increase linearly with the number of treatments, reported Suzanne L. Kilmer, M.D., at LASER 2012, the 32nd annual meeting of the American Society for Laser Medicine and Surgery.
Drug approvals give boost to armamentarium for treating AKs, BCCs
April 1st 2012The hot topics of discussion at Maui Derm 2012 were January’s Food and Drug Administration approval of two innovative products in the cutaneous oncology arena: Picato (ingenol mebutate, LEO Pharma) 0.015 percent gel and 0.05 percent gel for the treatment of actinic keratoses (AKs) and Erivedge (vismodegib, Genentech) for the treatment of advanced basal cell carcinoma. At MauiDerm I discussed the data on Picato and Keith Flaherty, M.D., an oncologist from Massachusetts General Hospital, discussed Erivedge.
Quick tips: Dermatologists offer assorted array of practical pearls
April 1st 2012Implementing a few simple ideas in clinical practice can have a significant impact in terms of saving time, saving money or improving patient outcomes. During a session at the 2011 Fall Clinical Dermatology Conference, members of the faculty offered a few personal pearls, each so easy and straightforward they could be encapsulated in a one-minute description.
Next chapter: Retired Naples derm creates clinic for working poor
March 16th 2012William Lascheid, M.D., was in his early 70s when he and his wife, Nancy, retired from four decades of dermatology practice. The couple lived in the lap of retirement luxury in Naples, Fla., and had dreamed about the days when they’d be free to sleep in and spend sunny afternoons by the pool.
FDA OKs shortcut path for biosimilars
February 15th 2012The Food and Drug Administration has created the first shortcut to the U.S. market for “biosimilar” medicines - cheaper versions of expensive and complex biologic drugs such as infliximab for rheumatoid arthritis, etanercept for plaque psoriasis and psoriatic arthritis, and erythropoietin for anemia.